Close
Contact us
Close

16th November 2020

The patent landscape behind the Nobel Prize awarded to CRISPR

Share this page:

The 2020 Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier in October for their work on the gene editing tool CRISPR/Cas 9, commonly referred to as CRISPR.

This Nobel Prize does not come without some controversy. Not only are the winners involved in a patent dispute relating to CRISPR, where Doudna’s and Charpentier’s interests are represented by the University of California while Feng Zhang, on the other side of the patent dispute, is active at The Broad Institute of MIT and Harvard and was notably not included in the award by the Nobel committee.

We have looked into the patents behind the CRISPR technology and discovered who the key players are in this space and how this is impacting the patent landscape.

Our article explores some of the following key findings:

  • The potential of CRISPR is undisputed, but who controls the patent assets?
  • Although universities are still in control of some of the largest patent portfolios relating to the CRISPR tool, commercial organisations are actively using and patenting this technology.
  • DuPont De Nemours and Regeneron Pharmaceuticals have comparatively small portfolios, but they are equally as important to the Harvard, MIT and Broad Institute portfolios.

Download the full article by filling out the form below.

If you’d like to learn more about how Cipher has enabled this Competitive Intelligence analysis, get in touch contact us directly.

‘CRISPR Nobel Prize’ PDF Download

download

CRISPR NOBEL PRIZE

Gain an insight into the companies behind this growing area of innovation

The report looks at the following areas:

  • key patent asset holders of the CRISPR technology
  • the evolving CRISPR patent landscape
  • the future of CRISPR as patent disputes are ongoing

 

CRISPR Nobel Prize article

Insights & Events

ANT Group IPO

ANT Group, the Alibaba FinTech giant is going for an IPO but what does its patent portfolio focus on?
Read more

Ams completes acquisition of Osram

Ams have final approval to buy OSRAM, but what does this mean for their patent portfolio?
Read more

Analog Devices buys Maxim

13th July 2020 saw Analog Devices agreeing a deal to buy Maxim Integrated in an all-stock transaction valued at US$21 billion. What does this mean for the analog semiconductor industry?
Read more

Banking Cybersecurity webinar

26 May 2020, 3:00pm BST View our webinar on Banking Cybersecurity where Cipher will shed light on key innovations helping reduce our exposure to online risks.
Read more

Digital Tokens: who is innovating to ensure safety in payments?

Discover how innovations are ensuring our payment security and what the patent landscape can tell us.
Read more

Fintech – Understanding the role of patents

Technologies that will disrupt and transform the future of banking
Read more

With Cipher you can…

Optimise your portfolio

Ensure you have the right portfolio to meet your strategic patenting objectives.

Read more

Gather competitor intelligence

Understand who’s doing what by automating patent to technology mapping.

Read more

Model cross licensing

Combine patent and revenue data to determine rational licensing outcomes.

Read more

Manage your budget

Justify patent budgets to CFOs and others to communicate the impact of your investment.

Read more

Conduct due diligence

Automate manual reviews for efficient execution of M&A and licensing transactions.

Read more

Tackle inbound patent assertion

Be prepared with evidence to create a fast and effective threat assessment.

Read more

Benchmark your portfolio

Assess your portfolio in comparison to other owners through your technology lens.

Read more

Monetise your portfolio

Identify opportunities to create value through licensing or sale of patent assets.

Read more

Improve your patent strategy now

Speak to one of our Cipher team today.